Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients

This study has been completed.
Information provided by (Responsible Party):
Egalet Ltd Identifier:
First received: March 9, 2007
Last updated: August 26, 2016
Last verified: August 2016
The purpose of the study is to determine the effect of Egalet® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients with pain due to cancer.

Condition Intervention Phase
Drug: Morphine Sulphate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Double-blind, Randomized, 2-way Cross-over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the Egalet® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus® 15-120 mg Twice Daily After 2 Weeks of Treatment

Resource links provided by NLM:

Further study details as provided by Egalet Ltd:

Primary Outcome Measures:
  • Use of rescue medication [ Time Frame: 2 weeks treatment ]

Secondary Outcome Measures:
  • Pain intensity [ Time Frame: 2 weeks treatment ]

Enrollment: 36
Study Start Date: August 2007
Study Completion Date: August 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Egalet® morphine Drug: Morphine Sulphate
Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
Active Comparator: MST Continus® Drug: Morphine Sulphate
Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient has stable strong opioid use equipotent to 30-240 mg oral morphine sulphate daily for a minimum of 2 weeks prior to entering the run-in phase.
  • The patient has opioid-sensitive pain caused by active cancer.
  • The patient is aged minimum 18 years.

Exclusion Criteria:

  • The patient has a life expectancy less than 2 months.
  • The patient has received chemotherapy or radiation therapy less than 4 weeks prior to entering run-in phase
  • Patients with medical conditions contraindicating morphine treatment
  • The patient has hepatic disease or impaired kidney function
  • The patient is taking monoamine oxidase inhibitors (MAOIs) or has taken a MAOI within two weeks prior to entering baseline.
  • The patient is taking other opioid agonists or antagonists, zidovudine or cimetidine.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00446069

Site 51
Kaunas, Lithuania
Site 50
Vilnius, Lithuania
Site 63
Bielsko-Biaia, Poland
Site 60
Bydgoszcz, Poland
Site 62
Poznań, Poland
Site 61
Warszawa, Poland
Site 64
Wrocław, Poland
Site 65
Włocławek, Poland
Sponsors and Collaborators
Egalet Ltd
Study Director: Christine Andersen, MSc Pharm Egalet A/S
  More Information

Responsible Party: Egalet Ltd Identifier: NCT00446069     History of Changes
Other Study ID Numbers: MP-EG-002
EudraCT number: 2006-006579-19
Study First Received: March 9, 2007
Last Updated: August 26, 2016

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on April 26, 2017